Clinical Observation of Rebamipide Triple Therapy in the Treatment of Gastric Ulcer with Bleeding
10.6039/j.issn.1001-0408.2017.06.13
- VernacularTitle:瑞巴派特三联疗法用于胃溃疡伴胃出血的临床观察
- Author:
Chenyu ZHU
;
Zhenhua YANG
- Keywords:
Rebamipide;
Omeprazole;
Aluminum magnesium carbonate;
Gastric ulcer;
Gastric bleeding;
Efficacy;
Safety
- From:
China Pharmacy
2017;28(6):766-769
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the efficacy and safety of rebamipide triple therapy in the treatment of gastric ulcer with bleeding. METHODS:130 patients with gastric ulcer with bleeding were randomly divided into control group(65 cases)and obser-vation group(65 cases). Control group received Omeprazole enteric-coated capsule 20 mg,orally,twice a day+Aluminum magne-sium carbonate tablet 500 mg,orally,once a day;observation group was additionally received Rebamipide tablet 0.1 g,orally,3 times a day. They were treated for 12 weeks. Clinical efficacy,remission time of belching,abdominal pain,bloating,hematemesis/hematochezia,clinical symptom score before and after treatment,rebleeding and the incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,remission time of symptoms and signs were significantly shorter than control group,the incidence of rebleeding was significantly lower than con-trol group,with statistical significances (P<0.05). Before treatment,there was no significant difference in the clinical symptom score (P>0.05). After treatment,the clinical symptom scores in 2 groups were significantly lower than before,and observation group was lower than control group,with statistical significances (P<0.05). And there was no significant difference in the inci-dence of adverse reactions (P>0.05). CONCLUSIONS:Rebamipide triple therapy shows obvious short-term efficacy in the treat-ment of gastric ulcer with bleeding,which can effectively improve patients'gastrointestinal symptoms,reduce rebleeding risk,and does not increase the incidence of adverse reactions.
